Zobrazeno 1 - 10
of 204
pro vyhledávání: ''
Autor:
Jun Ho, Yi, Seok Jin, Kim, Jeong-Ok, Lee, Gyeong-Won, Lee, Jae-Yong, Kwak, Hyeon-Seok, Eom, Jae-Cheol, Jo, Yoon Seok, Choi, Sung Yong, Oh, Won Seog, Kim
Publikováno v:
Anticancer Research. 42:6083-6089
The combination of bendamustine and rituximab (BR) is highly effective in both treatment-naïve and relapsed or refractory mantle cell lymphoma (MCL). Due to the rarity of MCL and limited accessibility of BR, clinical outcome from BR in the routine c
Autor:
Yoshihiro, Araki, Norio, Yamamoto, Toru, Maeda, Hiroaki, Kimura, Takashi, Ota, Shingo, Shimozaki, Takashi, Kato, Daisuke, Inoue, Takashi, Higuchi, Kensaku, Abe, Yuta, Taniguchi, Hiroyuki, Tsuchiya
Publikováno v:
Anticancer Research. 42:1555-1562
The management of soft-tissue tumors of 2-5 cm is not specified. We investigated the management of these cases.Among 105 cases with soft-tissue tumors from 2014 to 2021, 38 with tumors of 2-5 cm were retrospectively reviewed. The clinical characteris
Autor:
Yasuro, Futagawa, Shinji, Onda, Shuichi, Fujioka, Teruyuki, Usuba, Yukio, Nakabayashi, Takeyuki, Misawa, Tomoyoshi, Okamoto, Toru, Ikegami
Publikováno v:
Anticancer Research. 42:1579-1588
Management strategies for pseudoaneurysm rupture after pancreatic resection have not yet been firmly established due to its low incidence and effects of environmental variability among centers. This study aimed to provide a basis for treatment strate
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
Autor:
Hideaki, Suematsu, Kazuki, Kano, Takanobu, Yamada, Itaru, Hashimoto, Hayato, Watanabe, Kosuke, Takahashi, Mamoru, Watanabe, Kei, Hayashi, Yoshihiro, Kaneta, Mitsuhiro, Furuta, Yasuhiro, Inokuchi, Nozomu, Machida, Toru, Aoyama, Hiroshi, Tamagawa, Norio, Yukawa, Yasushi, Rino, Munetaka, Masuda, Takashi, Ogata, Takashi, Oshima
Publikováno v:
Anticancer Research. 42:1535-1540
To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).Patients with unresectable advanced GC and recurrenc
Autor:
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer Research. 42:1607-1613
There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metas
Publikováno v:
Anticancer Research. 42:1359-1365
To investigate the association between external beam radiotherapy (EBRT) and the incidence of second primary tumors in patients with thyroid cancer.Data were extracted from the Surveillance, Epidemiology, and End Results 9 database. The study cohort
Autor:
KAZUKI HASHIMOTO, RYUJI YASUMATSU, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, TAKASHI NAKAGAWA
Publikováno v:
Anticancer Research. 42:981-989
The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear.We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The ex
Autor:
Kodai, Tomioka, Takeshi, Aoki, Makoto, Watanabe, Yuta, Enami, Akira, Fujimori, Tomotake, Koizumi, Satoru, Goto, Kimiyasu, Yamazaki, Koji, Otsuka, Masahiko, Murakami
Publikováno v:
Anticancer Research. 42:1115-1121
To evaluate the complication rates and risk factors associated with transumbilical incision (TUI) and comprehensively examine differences according to the procedures using propensity score matching.The study involved 737 patients who underwent laparo
Autor:
Minoru, Horiuchi, Tetsuya, Oguri, Yusuke, Kagawa, Kazuki, Sone, Satoshi, Fukuda, Takehiro, Uemura, Osamu, Takakuwa, Ken, Maeno, Kennsuke, Fukumitsu, Yoshihiro, Kanemitsu, Tomoko, Tajiri, Hirotsugu, Ohkubo, Masaya, Takemura, Yutaka, Ito, Akio, Niimi
Publikováno v:
Anticancer Research. 42:1073-1079
The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear.We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital.Of the 65 patients, 53 w
Publikováno v:
Anticancer Research. 42:1001-1006
Formation of stoma during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) is often performed to reduce the risk of anastomotic leak. Subsequent stoma reversal provides a unique oppo